| COMPANY |
DexCom, Inc. |
| COURT |
United States District Court for the Southern District of California |
| CASE NUMBER |
24-cv-01485 |
| JUDGE |
The Hon. Robert Steven Huie |
| CLASS PERIOD |
April 28, 2023 through July 25, 2024 |
| SECURITY TYPE |
Securities |
Class Background:
Throughout the Class Period, on earnings and shareholder calls, Defendants continually praised their alleged growth, foreseeing record numbers of new patients and outpacing their prior fiscal year’s gross margins, while continually minimizing the risks associated with scaling their customer transition to the G7 platform, as well as those associated with seasonality and the potential impact of the macroeconomic environment on the company’s profitability.
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DexCom’s communications about growth and anticipated margins were unreasonably optimistic due to its reliance on attracting new customers; (2) DexCom was struggling to keep existing distribution channels successful; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
Defendants filed the Motion to Dismiss the First Amended Complaint on June 11, 2025. The Motion is pending decision before the Court. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.